TY - JOUR
T1 - The effectiveness of COVID-19 vaccines in Latin America, 2021
T2 - a multicenter regional case–control study
AU - Regional COVID-19 VE in Adults Study Working Group
AU - Kahn, Rebecca
AU - Janusz, Cara B.
AU - Castro, Marcia C.
AU - da Rocha Matos, Aline
AU - Domingues, Carla
AU - Ponmattam, Jamie
AU - Rey-Benito, Gloria
AU - Toscano, Cristiana M.
AU - Helena de Oliveira, Lucia
AU - Rearte, Analia
AU - Uriarte, Ignacio Leandro
AU - Baumester, Elsa
AU - Borda, Maria Elena
AU - Diaz Cordoba, Miguel
AU - Facundo Petrina, Juan
AU - Consiglio, Ezequiel
AU - Vizzotti, Carla
AU - Guimarães de Noronha, Tatiana
AU - Gomes Mourão, Maria Paula
AU - Baima Colares, Jeova Keny
AU - Raboni, Sonia Mara
AU - Vanni, Tazio
AU - Guzman, Lely
AU - Pontes Lucena, Adriana Regina Farias
AU - Santolaya, Maria Elena
AU - Urquidi, Cinthya
AU - Cortes, Claudia P.
AU - Usedo Lopez, Pedro Pablo
AU - Benitez, Rosana
AU - Latorre, Veronica Menares
AU - Moller Roth, Andrea
AU - Cerda, Iván Brstilo
AU - Santillana, Solange
AU - Abaakouk, Zohra
AU - Caicedo, Angel Paternina
AU - Alvis Guzman, Nelson
AU - Fernandez Mercado, Juan Carlos
AU - de la Hoz Restrepo, Fernando
AU - Santiago Quevedo, David
AU - Rios Oliveros, Sofia
AU - Moyano Romero, Diane
N1 - © 2023 Published by Elsevier Ltd.
PY - 2023/4
Y1 - 2023/4
N2 - Background: As of September 2022, nearly 1.3 billion doses of COVID-19 vaccine products have been administered in Latin America and the Caribbean, where 27% of global COVID-19 deaths have occurred. This study aimed to estimate the effectiveness of COVID-19 vaccines against lab-confirmed COVID-19 related hospitalizations and deaths among adults in Argentina, Brazil, Chile, and Colombia. Methods: Using a test-negative case control design, we evaluated the effectiveness of a primary vaccination series considering six COVID-19 vaccine products (Sputnik V, mRNA-1273, CoronaVac, ChAdOx1, BNT162b2, Ad26.COV2.S) against lab-confirmed COVID-19 hospitalizations and deaths among 83,708 hospitalized adults from February–December, 2021. Data from hospitalization records, COVID surveillance, and vaccination registries were used. Vaccine effectiveness was estimated using logistic regression ((1-OR) x 100). Findings: The average age of participants was 56.7 (SD = 17.5), and 45,894 (54.8%) were male. Adjusted VE (aVE) estimates for full vaccination against hospitalization were 82% for mRNA-1273 (95% confidence interval (CI) = −30 to 98%), 76% (71%–81%) for BNT162b2, 65% (61–68%) for ChAdOx1, 57% (10–79%) for Sputnik V, 53% (50–56%) for CoronaVac, and 46% (23–62%) for Ad26.COV2.S. Estimates, particularly for CoronaVac, varied by variant. Decreasing aVE was estimated as age increased, particularly for CoronaVac and ChAdOx1. aVE estimates against death were generally higher, with 100% (CI not estimated) for mRNA-1273, 82% (69–90%) for BNT162b2, 73% (69–77%) for ChAdOx1, 65% (60–67%) for CoronaVac, 38% (−75 to 78%) for Sputnik V, 6% (−58 to 44%) for Ad26.COV2.S. Interpretation: Primary series vaccination with available COVID-19 vaccine products was effective against COVID-19 hospitalization and mortality. Effectiveness varied by product and declined with increasing age. Funding: This study was funded by the Pan-American Health Organization (PAHO, World Health Organization (WHO)). PAHO convened and led the study implementation.
AB - Background: As of September 2022, nearly 1.3 billion doses of COVID-19 vaccine products have been administered in Latin America and the Caribbean, where 27% of global COVID-19 deaths have occurred. This study aimed to estimate the effectiveness of COVID-19 vaccines against lab-confirmed COVID-19 related hospitalizations and deaths among adults in Argentina, Brazil, Chile, and Colombia. Methods: Using a test-negative case control design, we evaluated the effectiveness of a primary vaccination series considering six COVID-19 vaccine products (Sputnik V, mRNA-1273, CoronaVac, ChAdOx1, BNT162b2, Ad26.COV2.S) against lab-confirmed COVID-19 hospitalizations and deaths among 83,708 hospitalized adults from February–December, 2021. Data from hospitalization records, COVID surveillance, and vaccination registries were used. Vaccine effectiveness was estimated using logistic regression ((1-OR) x 100). Findings: The average age of participants was 56.7 (SD = 17.5), and 45,894 (54.8%) were male. Adjusted VE (aVE) estimates for full vaccination against hospitalization were 82% for mRNA-1273 (95% confidence interval (CI) = −30 to 98%), 76% (71%–81%) for BNT162b2, 65% (61–68%) for ChAdOx1, 57% (10–79%) for Sputnik V, 53% (50–56%) for CoronaVac, and 46% (23–62%) for Ad26.COV2.S. Estimates, particularly for CoronaVac, varied by variant. Decreasing aVE was estimated as age increased, particularly for CoronaVac and ChAdOx1. aVE estimates against death were generally higher, with 100% (CI not estimated) for mRNA-1273, 82% (69–90%) for BNT162b2, 73% (69–77%) for ChAdOx1, 65% (60–67%) for CoronaVac, 38% (−75 to 78%) for Sputnik V, 6% (−58 to 44%) for Ad26.COV2.S. Interpretation: Primary series vaccination with available COVID-19 vaccine products was effective against COVID-19 hospitalization and mortality. Effectiveness varied by product and declined with increasing age. Funding: This study was funded by the Pan-American Health Organization (PAHO, World Health Organization (WHO)). PAHO convened and led the study implementation.
KW - argentina
KW - brazil
KW - case
KW - chile
KW - control
KW - covid-19 vaccination
KW - test-negative
KW - vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85152373727&partnerID=8YFLogxK
U2 - 10.1016/j.lana.2023.100474
DO - 10.1016/j.lana.2023.100474
M3 - Article
C2 - 37008741
AN - SCOPUS:85152373727
SN - 2667-193X
VL - 20
SP - 100474
JO - Lancet Regional Health - Americas
JF - Lancet Regional Health - Americas
M1 - 100474
ER -
